epocrates

Webinar recap: GLP-1s in practice - Insights, challenges, and opportunities in patient care

May 8, 2025

This recent webinar, hosted by epocrates, provided an in-depth analysis of GLP-1 receptor agonists (GLP-1 RAs) and their role in chronic disease management. The panel included Dr. Naushira Pandya, a geriatrician and endocrinologist from Nova Southeastern University; Dr. Sun Kim, an endocrinologist at Stanford University; and Dr. Irl B. Hirsch, an endocrinologist at the University of Washington. They discussed the latest advancements, clinical applications, and future directions of GLP-1 therapies, offering insights into their efficacy, safety, and practical considerations in patient care.

Webinar length: 56 min.

Key takeaways

1. Efficacy and safety: GLP-1 RAs have demonstrated significant benefits in managing glycemic control, promoting weight loss, and reducing major adverse CV events. These therapies are effective in both T2DM and obesity, with additional benefits for CV and renal health.
2. Real-world applications: Clinical cases presented by the panelists showed that GLP-1 therapies can lead to substantial improvements in patient outcomes. For example, patients with T2DM experienced reduced insulin requirements and improved blood glucose levels, while those with obesity saw significant weight loss and increased motivation for lifestyle changes.
3. Patient education and adherence: Educating patients about the mechanism of action, administration, and potential side effects of GLP-1 RAs is crucial. Strategies to manage common side effects, such as nausea and other GI issues, include advising smaller, more frequent meals, adequate hydration, and gradual dose escalation. Proper patient education can improve adherence and overall treatment outcomes.
4. Access and affordability: The high cost and insurance coverage challenges of GLP-1 RAs remain significant barriers. The panelists discussed practical solutions, such as utilizing patient assistance programs, exploring dosing flexibility, and considering alternative sources like Canadian pharmacies. However, they cautioned against the use of compounded GLP-1 therapies due to safety concerns.
5. Future directions: The panel highlighted ongoing research and potential new indications for GLP-1 RAs, including their use in liver disease and emerging oral formulations. Staying informed about these developments is essential for optimizing patient care and expanding the therapeutic applications of GLP-1 therapies.

Source:

(2025, April 28). epocrates. GLP-1s in Practice: Insights, Challenges, and Opportunities in Patient Care [Webinar].